Bolt Biotherapeutics reports Q2 2026 operating loss of $8.4M; cash $18.1M funds into Q1 2027

Bolt Biotherapeutics, Inc.

Cash, equivalents and marketable securities $18.1M as of Jun 30, 2026; expected to fund operations into 1Q 2027.
Collaboration revenue $5K vs $1.8M in Q2 2025; R&D expenses $5.1M vs $7.5M; G&A $2.4M vs $3.5M.
Loss from operations $8.4M in Q2 2026 vs $9.2M in Q2 2025, driven by restructuring-related cost reductions.
BDC-4182 Phase 1/2 in gastric/GEJ cancer ongoing; Cohort 4 dosing at 4.0 mg/kg; initial data expected with 3Q 2026 results.
CEO Willie Quinn cites well-tolerated profile and activity consistent with immune-stimulating mechanism for BDC-4182.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.